Phase 1/1b study of SY-5609, a selective and potent CDK7 inhibitor, in advanced solid tumors and in 2L/3L pancreatic ductal adenocarcinoma (PDAC) in combination with gemcitabine +/- nab-paclitaxel.

MLA

Bashir, Babar, et al. “Phase 1/1b Study of SY-5609, a Selective and Potent CDK7 Inhibitor, in Advanced Solid Tumors and in 2L/3L Pancreatic Ductal Adenocarcinoma (PDAC) in Combination with Gemcitabine +/- Nab-Paclitaxel.” Journal of Clinical Oncology, vol. 41, June 2023, p. 3080. EBSCOhost, https://doi.org/10.1200/JCO.2023.41.16_suppl.3080.

APA

Bashir, B., Sharma, M., Juric, D., Papadopoulos, K. P., Hamilton, E. P., Richardson, D. L., Shapiro, G., Sahai, V., Mettu, N. B., Wainberg, Z. A., Alese, O. B., Dragovich, T., Hodgson, G., Henry, S., Hall, T., Paul, S., Roth, D. A., Kelly, M., Abdul Malak, T., & Klimek, V. (2023). Phase 1/1b study of SY-5609, a selective and potent CDK7 inhibitor, in advanced solid tumors and in 2L/3L pancreatic ductal adenocarcinoma (PDAC) in combination with gemcitabine +/- nab-paclitaxel. Journal of Clinical Oncology, 41, 3080. https://doi.org/10.1200/JCO.2023.41.16_suppl.3080

Chicago

Bashir, Babar, Manish Sharma, Dejan Juric, Kyriakos P. Papadopoulos, Erika P. Hamilton, Debra L. Richardson, Geoffrey Shapiro, et al. 2023. “Phase 1/1b Study of SY-5609, a Selective and Potent CDK7 Inhibitor, in Advanced Solid Tumors and in 2L/3L Pancreatic Ductal Adenocarcinoma (PDAC) in Combination with Gemcitabine +/- Nab-Paclitaxel.” Journal of Clinical Oncology 41 (June): 3080. doi:10.1200/JCO.2023.41.16_suppl.3080.